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Glioblastoma Multiforme (GBM) is the most common and malignant form of the 
primary brain tumor. Due to its highly invasive nature, current treatment options 
have not been able to improve the survival rate in past 20 years. In order to 
discover GBM therapeutic targets, omics technologies have been widely used to 
identify potential biomarkers.  
 This research study focused on investigating lipid biomarkers of human 
GBM orthotopic mouse models employing mass spectrometry. Human tumor cell 
lines GBM10 and GBM43 were injected in the right cerebral hemisphere and 
flank sites in NOD/SCID mice (n = 10 mice per group). Left cerebral hemispheres 
of the mouse brains were harvested as control tissue.  After harvesting brain and 
flank tumors and control brain from the xenograft models, protein, metabolites, 
and lipids of tumor samples were collected through the simple extraction 
procedure. These samples were analyzed by reverse phase high performance 
liquid chromatography – Fourier transform ion cyclotron resonance mass 




of all MS instruments, which is ideal for complex mixtures such as GBM tissue. 
Spectra obtained from the FTMS analysis were analyzed using Student t-tests to 
detect significant differences in tissue profiles at a level of p = 0.05. Compounds 
below this threshold were identified through a database using the m/z ratio. 
 Lipidomic analysis indicated the possible differentially expressed lipids 
classes in GBM tissues, and connected to metabolic pathways, tumor 
proliferation and immunodepression. Most significantly expressed lipids were 
glycerophospholipids, glycerophosphocholines, glycerophoserines, and 
triradylglycerols. Accompanying these studies is a collaborative effort to improve 
the effectiveness and efficiency of computational pipelines that are imperative to 
the analytics, visualization, identification, and interpretation of the omics data. 
Only by carefully integrating the computational pipelines can we successfully 
perform the types of integrative studies needed to advance the identification of 
cancer biomarkers for diagnosis and prognosis, and our integrative studies serve 
















CHAPTER 1.  INTRODUCTION 
 This chapter introduces the overview of lipidomic analysis of Glioblastoma 
Multiforme (GBM) research study. This chapter provides a statement of purpose 
in GBM cancer studies, research questions, scope and significance of the study 
that explain needs of knowledge in cancer lipids, definitions of key terms, 
assumptions, limitations, and delimitations of this research study.  
 
1.1 Statement of Purpose 
 Cancer has become one of the most common diseases in people’s lives. 
Although many scientists attempt to find the effective way of treatment for cancer, 
the success rate has not dramatically increased over the past several decades. 
Glioblastoma Multiforme (GBM) is one of the most aggressive types of cancer 
that occurs in the human brain. Current treatment options of glioblastoma have 
not increased survival rates of GBM patients beyond 20 years. The purpose of 
this research is to discover potential cancer targets of GBM by using cutting edge 
technologies to investigate proteins, metabolites, and lipids of orthotopic and 
subcutaneous xenograft mouse tumor tissues. Figure 1.1 overviews the general 
cancer proteomics workflow and therapeutic goals using different existing models. 




targeting biomarkers. This experiment includes analysis of metabolites and lipids 
of GBM to explain distinct characteristics of GBM along with protein biomarkers. 
This thesis covers the lipidomics part of the project. 
 
Figure 1.1. Generalized workflow for cancer proteomics studies using model 
systems and clinical samples (Collins et al., 2009).  
 
 Another important goal of this study is the comparison of various existing 
cancer models to explain the morphology changes of cancer cells in different 
microenvironment and reliability of the models. Cancer models such as human in 
vitro, mouse in vivo, and naturally occurring animal cancer play critical roles in 
cancer research. This research study utilized orthotopic and subcutaneous 
xenograft mouse models and two different human GBM cell types (GBM10 and 




these results were examined to discover metabolic characteristics of the GBM 
that can potentially be compared with metabolite and protein data in the future.  
 
 
1.2 Research Questions 
• What are the similarities and differences of molecular profiles between 
brain (orthotopic) and flank (subcutaneous) tumors in mouse xenograft 
model? 
• Are there biomarkers in GBM10 and GBM43 that are related to metabolic 
properties of GBM? 
 
1.3 Scope 
 The scope of this study was lipidomic analysis of Glioblastoma Multiforme 
(GBM) using electrospray ionization Fourier transform mass spectrometry (ESI-
FTMS; 7 T Bruker Instrument) and various data analysis tools. The research 
focused on the characterization of lipids in orthotopic and subcutaneous mouse 
xenograft models using comparative analysis to investigate the characteristics of 
GBM that can possibly provide evidence in the unique patterns of GBM 
metabolism. Furthermore, this data explained the interactions between 
metabolite and protein profiling data for future work. Global lipid profiling data 
from mass spectrometry was analyzed using various bioinformatics tools 
(MzMine2 and LIPID MAPS) and statistical method to identify the significant lipid 






 Technology plays a significant role in disease studies, including cancer 
research. Omics studies have been employed in disease studies to investigate 
the characteristics of the disease and to discover novel biomarkers. According to 
The Cancer Genome Atlas, more than 500 human GBM tumors have been 
sequenced and characterized (Brennan et al., 2013). In addition to active 
investigation of GBM genomics, whole proteome analyses were performed using 
various human samples in the past decade (Niclou, Fack, & Rajcevic, 2010). 
Even though genomics and proteomics provide knowledge of GBM, these 
studies fail to suggest effective targets for therapy.  
 Lipidomics is a relatively new field, introduced in 2003 by Han and Gross 
(Niclou, Fack & Rajcevic, 2010). Lipids in GBM have not been studied as much 
as proteins and genomes due to biological and technical challenges. However, 
lipids have many important functions in biological systems, such as energy 
storage, structural components, cell membrane composition, and cell signaling. 
Moreover, human brain tissue consists of five to 15% lipids, the highest amount 
of lipids in comparison to other organs within the body (Campanella, 1992). Lipid 
metabolism regulated by oncogenic signaling pathways is known to play an 
important role in cancer initiation and progression (Zhang, 2010). However, the 
role of lipids in cancer studies is still poorly understood due to biological and 
technical difficulties (Shevchenko & Simons, 2010; Tripathy, 2011). As a result of 
lack of lipidome information, genomic and proteomic profiles have not been 




investigate protein levels of tumor tissues in order to predict the lipid function and 
composition. These studies also tend to focus on the importance of lipid 
synthesis.  
 In order to explore discovery lipidomics, the two most common types of 
xenograft mouse models were used to generate GBM tumors from human GBM 
cells lines. Human GBM10 and GBM43 that were provided by Mayo Clinic, 
Rochester, Minnesota, were injected into both subcutaneous (flank) and 
orthotopic (intracranial) sites. Tumors from different xenograft models may 
represent different histopathologic, genetic, and growth properties of GBM. From 
our data, we hypothesized that fatty acid oxidation plays a critical role in 
glioblastoma development and malignancy of the tumor as much as lipid 
synthesis. To test this assumption, proteomic and metabolomic data will be used 
to validate the metabolic patterns in GBM. This study is also a collaborative effort 
to improve the effectiveness and efficiency of computational pipelines that are 
imperative to the analytics, visualization, identification, and interpretation of the 
omics data through integration of existing analytical algorithms. Integrative 
studies serve as a case study for our pipeline advancement efforts and 
identification of therapeutic biomarkers.  
 Integrated omics study can characterize the distinct biological properties 
of GBM that can lead to effective way of targeting malignant brain tumors. This 
thesis covers the lipidomic element of the project.  A novel extraction method 
used to collect proteins, metabolites, and lipids in a single sample preparation 




different biological levels of samples to generate the global profiling data with the 
highest sensitivity and mass accuracy among existing instruments. Another 
important goal of this study is to compare existing models to investigate the 
similarities and differences between different GBM models to improve the cancer 
modeling system and justify how well these models can mimic human GBM. The 
results of the study provide insights into the improvement of outcomes in the 
discovery of novel GBM biomarkers and a GBM modeling system.  
 
1.5 Definitions of Key Terms 
apoptosis – a distinct process of cell death that is responsible for cell death (Kerr 
& Winterford, 1994).  
biomarker – molecular indicator that distinguish normal or diseased process 
states in the body (Tainsky, 2009). 
carcinogen – compound that causes formation of DNA adducts. It has an ability 
to initiate various genetic mutations that cause cancer (Herbst et al., 2008).  
lipidomics – system-level identification and quantification of pathways and 
networks of cellular lipids, molecular species, and interactions (Tripathy, 
2011).  
mass spectrometry – the study of matter that is transformed into gas-phase ions 
and detect by mass/charge ratio (Murray et al., 2013) 
metabolites – small molecules that have functions in cellular state and are 




metabolomics – the global quantitative study of metabolites using omics 
technologies that utilizes the analytical instrumentation with pattern 
recognition techniques to investigate changes in metabolites (Beger, 
2013). 
metastasis – cancer cell detachment from the primary tumor site and migration to 
other body sites through the lymphatic or blood circulatory systems 
(Chiang & Massague, 2008; Gupta & Massague, 2006).  
oncogene – a gene that is mutated by carcinogens and causes uncontrollable 
cell growth that becomes cancer cells (Herbst et al., 2008).  
proteomics – technology-driven scientific study of proteins, especially their 
 changes, proteomes, post-translational modifications, and interactions 
 (Fountoulakis, 2001). 
Temozolomide (TMZ) – a DNA alkylating agent that demonstrates antitumor 
activity used for glioma treatment (Stupp et al., 2005).  
tumorigenesis – genetic alterations that generate the progressive transformation 
of normal cells into a highly malignant tumor (Hanahan & Weinberg, 2000). 
xenograft – in cancer studies, human tumor cell transplantation into 
 immunocompromised mice that do not reject human cells (Richmond & Su, 
 2008).  
 
1.6 Assumptions 
 The following assumptions are inherent to the pursuit of this study: 




• Lipid profile data that is generated by mass spectrometry is accurate.  
• In vivo tumor environment can change morphology of GBM.  
• Lipid database matches theoretical mass/charge ratio of lipids from GBM. 
 
1.7 Limitations 
 The following limitations are inherent to the pursuit of this study:  
• Human GBM10 and GBM43 were used to generate tumors in mouse 
xenograft models and generate data.  
• Orthotopic and subcutaneous mouse xenograft tumors were used as 
different cancer models.  




 The following delimitations are inherent to the pursuit of this study:  
• Not all types of GBM samples were used to represent GBM results. 
• There was no comparison of results using different bioinformatics tools 
other than MzMine2 and LIPID MAPS.  
• Existing cancer models other than mouse were not examined for the 






 This chapter has provided an overview of the research study, including 
statement of purpose, research question, scope, significance, definitions of key 
terms, assumptions, limitations, and delimitations. The next chapter provides an 
overview of glioblastoma, current treatment options, proteomics, metabolomics 


















CHAPTER 2.  REVIEW OF RELEVANT LITERATURE 
Glioblastoma (GBM) is known as an aggressive form of brain tumor that 
has a low survival rate. This chapter provides an overview of glioblastoma, 
current treatment options, and research focus. It introduces current and future 
treatment options of GBM and optimization of animal models to understand the 
characteristics of human GBM. Characteristics of omics studies are also 
discussed.   
 
2.1 Glioblastoma Multiforme 
 Glioblastoma Multiforme (GBM) is the most common form of primary brain 
tumor (Pelloski & Gilbert, 2007). GBM is also called a grade IV astrocytoma 
(Kleihues, Burder, & Scheithauer, 1993). GBM represents about 50% of all 
gliomas and is a distinct primary tumor type (Jellinger, 1978). Figure 2.1 shows 
the distributions of primary brain and CNS tumors (figure 2.1 A) and primary 
brain gliomas in the United states from 2004 to 2006 (figure 2.1 B). Despite many 
treatment options, it is still incurable and has less than a two-year survival period 
from the time of diagnosis. GBM can occur at all ages and most frequently in the 
elderly (Ohgaki et al., 2004). Progression of gliomas shows genetic and 




(PTEN, TP53, INK4A/p16, ARF/p19, Rb) or activation of oncogentic pathways 
(p21-Ras, PI3-kinase, EGFR, CDK4, MDM2) (Agnihotri et al., 2013).  
 
 
Figure 2.1. Primary brain tumor distributions (Agnihotri et al, 2013). 
 
 Glioblastoma Multiforme is highly invasive and malignant and the tumor 
cells migrate great distances from the primary tumor site by its diffuse infiltration 
characteristic. Tumor cells disseminate from the primary tumor site and migrate 
along the white matter tracks, the basal lamina of brain blood vessels, or in 
between the glia limitans and the pia matter. Invasion of GBM steps include 




hyaluronan-mediated motility receptor (HMMR), degradation of the ECM, and 
altered cell contractility and motility (Agnihotri et al., 2013).   
 
2.2 Treatment Options in Glioblastoma 
 Prognosis of Glioblastoma (GBM) have not been changed over several 
decades even though diagnostic modalities, surgical techniques, and adjuvant 
treatment strategies have been developed dramatically in the last 30 years 
(Oertel, von Buttlar, Schroeder, & Gaab, 2005) . GBM has a median survival time 
of approximately 12 to 15 months from diagnosis. The two-year survival rate is 
only about five to 15% (Stupp et al., 2005). Due to the extremely aggressive 
nature of GBM, current treatment options are not designed to improve patients’ 
quality of life, but simply to extend their life (Lipsitz et al., 2003). There are 
several treatment options for glioma treatment.  
 
2.2.1 Current Therapies 
 Surgery may eliminate some tumor tissue using maximal resection and 
intra-operative resection (local treatment) (Pelloski & Gilbert, 2007). The study 
shows that surgery may extend survival times approximately 14 weeks. However, 
GBM surgery is very difficult because of GBM’s invasive, diffuse, and poorly 
defined borders of the tumor (Agnihotri et al., 2013). Autopsy studies show that 
malignant cells are found in brain distant from the primary site (Pelloski & Gilbert, 
2007). GMB is incurable by surgery in the majority of patients due to more than 




method is important for managing the tumor in patients. Radiotherapy and 
chemotherapy are usually administered after surgery to increase survival rate of 
GBM patients (Reardon & Wen, 2006).  
 Due to difficulties of design and implementation, only a few prospective 
surgical trials have been attempted. A surgical design utilizing 5-aminolevulinic 
acid has been recently attempted in Germany. This method uses 5-
aminolevulinic acid in order to help surgeons perform maximized resection of 
contrast-enhancing portion of GBM (Pichlmeier et al., 2008). However, current 
surgical methods have not increased patients’ overall survival period dramatically.  
 Radiation is broadly used to decrease the GBM tumor site in the brain and 
slow the process of cancer and it is commonly coupled with the surgery method. 
However, GBM is difficult to treat with radiation due to GBM’s tendency to widely 
infiltrate brain tissues. (Pelloski & Gilbert, 2007). No perspective radiation studies 
have been attempted and existing techniques, intensity-modulated RT (IMRT) 
and traditional 3-dimensional EBRT, have not shown improved results in GBM 
therapy (Clarke et al., 2010).  
 Another brain tumor therapy that is used most commonly is chemotherapy. 
Temozolomide (TMZ) is the most widely used GBM chemotherapy drug that has 
great oral bioavailability, no significant drug-drug interactions, and no cumulative 
myelotoxity. This chemotherapeutic agent has a potential to improve overall 
survival in human GBM patients. TMZ increased the long-term survival rate from 




 Investigation of TMZ combination with other cytotoxic chemotherapies and 
with cytostatic agents may increase survival period.  However, resistance of 
GBM to chemotherapy is common (Reardon & Wen, 2006).  
 
2.2.2 Advances in Therapies 
 Despite these treatment options, recurrent glioblastoma patients gain only 
minimal or modest improvement from current treatments. The objectives of GBM 
therapy investigation are to target cellular pathways or specific biomarkers in 
pathogenesis and to identify molecular properties of cancer that predict a 
therapeutic response. On-going GBM research focuses on inhibition of tumor 
function, survival, proliferation, apoptosis, invasion, and angionesis (Agnihotri et 
al., 2013). Much current research investigates the neural signaling pathway of 
glioblastoma to block tumor growth. Knowledge of signaling pathways has 
elucidated new potential therapeutic targets. A large number of new glioblastoma 
drugs target these signaling pathways. Since proliferation and survival pathways 
are mostly regulated by growth factors and their receptors, inhibition of these 
pathways and receptors can eliminate and prevent tumor formation in brain. 
There are also many studies to inhibit angiogenesis of tumors, Ras/MAPK and 
PI3K/Akt pathways, proteasomes, and histone deacetylases (Reardon & Wen, 
2006).  
 Another advance in the treatment of glioblastoma is an antiangiogenic 
therapy. The formation of new blood vessels, angiogenesis, plays an important 




nutrients, and growth factors through blood vessels (Hamahan & Folkman, 1997). 
In malignant gliomas, angiogenesis is associated with an increase in vascular 
endothelial growth factor (VEGF). VEGF is a protein that promotes formation of 
new blood vessels, which stimulates endothelial cell growth, migration, and 
survival from preexisting blood vessels (Hicklin & Ellis, 2005). There are several 
drugs that are on trial for malignant gliomas. Bevacizumab is a monoclonal anti-
VEGF antibody that is in several phase 2 trials. However, Bevacizumab has 
serious toxicity that could promote a more invasive aggressive tumor and shorten 
survival period (Stupp et al., 2009). Cilengitide is an inhibitor of αvβ3 and αvβ5 
integrin receptors, which are activated by VEGF and promote angiogenesis 
(Meredith et al., 1993). It has been investigated in phase 2 trials with and without 
radiation/Temozolomide on recurrent GBM (Stupp et al., 2007). Another drug that 
is in trial for antiangiogenesis is Talampanel. Talampanel is a glutamate receptor 
blocker that inhibits the proliferation and migration of GBM. It showed statistically 
significant improvement in GBM patients and will be investigated in a phase 3 
trial (Grossman et al., 2009).  
 A variety of other cancer therapeutic approaches are under active 
investigation. Gene therapy uses the insertion or modification of genes into a cell 
to treat cancer. Gene delivery can be performed using vectors from viruses or 
synthetic vectors such as nanoparticles. However, clinical trials have been limited 
due to a short distance of the delivery site (Clarke, et al., 2010).  
 Immunotherapeutic therapy has been studied for glioma. There are two 




The goal of active immunotherapy is to promote long-term immune responses by 
up-regulating immunity against the tumor. Long-term immunity could potentially 
prevent future tumor recurrence (Clarke, et al., 2010). Tumor vaccines such as 
EGFRvIII and dendritic cells are in trial to improve GBM treatment (Luptrawan et 
al., 2008; Choi et al., 2009). Passive immunotherapy attempts to achieve an 
immediate effect of immune response for short-term immunity by transferring 
immune effectors. Antibody-mediated drug delivery has been used to increase 
the local drug concentration and minimize nonspecific systemic exposure 
(Mitchell & Sampson, 2009). Although there are various approaches of GBM 
treatment, many treatment options are still in trials and they have not led to a 
significant increase in the survival period of GBM patients.  
 
2.3 Animal Models of Glioblastoma 
 Proteomic studies using clinically relevant model systems have potential 
to discover novel cancer target molecules. Cancer models are investigated to 
understand disease progression, tumor adaption, and treatment responses. 
Animal models help researchers to design more controlled experiments, 
including reproducible sampling, duplicable experiments, and tumor progression 
over different time periods. Although models have several advantages in clinical 






2.3.1 Current Animal Models 
 Human/rat xenograft glioblastoma models are commonly used to identify 
the protein expression in highly malignant, non-angiogenic brain tumors (Niclou, 
Fack, & Rajcevic, 2010). Figure 2.2 shows the types of mouse models in cancer 
research, advantages, and disadvantages among different mouse models. The 
features of ideal GBM models should include good representation of human 
GBM, gene, and metabolism alteration, reproducibility, and similar tumor 
progression progress (Yi, Hua, & Lin, 2011). These models are also required to 
mimic physiological tumor traits, including tumor invasive growth, 
neovascularization, necrosis, and psedopalisading cells (Miura et al., 2010).  
 




Current GBM mouse models are highly efficient for tumor formation, appropriate 
tumor growth rate, and an accurate tumor growth site. Although mouse models 
have been playing important role in GBM research for over 30 years, these 
models have had limitations in providing important biological and pathological 
properties of human GBM ( Yi, Hua, & Lin, 2011). The xenograft tumor models 
lose genomic and phenotypic properties of human tumor (Martens et al., 2008; 
Sausville and Burger, 2006; Taillandier et al., 2003). In the result, these models 
does not represent GBM heterogeneity (Bonavia et al., 2011; Lee et al., 2006; 
Verhaak et al., 2010). 
 Rats and rodents are good models to understand human cancer as they 
are cost effective and time efficient (Pang & Argyle, 2009). However, rat models 
have not been effective to improve human GBM treatment due to the 
physiological differences between humans and rats. Successful treatment from 
rodents often does not translate into the same success in human patients (Pang 
& Argyle, 2009). Mice models show similar results as rat models. Many drugs 
that are effective treatments for mice show low success rates in human clinical 
trials due to low efficiency or toxicity to human patients.  
 In this research two different xenograft tumors, flank tumors and brain 
tumors, were used to discover potential biomarkers, identify distinct patterns of 
metabolites and lipids of GBM, and to explore the similarities and differences of 
mouse tumors and human GBM. Flank tumors usually have excessive tumor 
growth and low immune response on the tumor site (Speroni et al., 2009). Flank 




Orthotopic tumors have higher cellular influx and higher local immune response. 
Compared to flank tumors, orthotopic tumors are smaller and have shorter 
survival rates. These tumors are also highly vascularized (Speroni et al., 2009). 
Although orthotopic models provide metastatic properties, they often fail to 
represent the traits of human GBM invasion, diffuse infiltration of the cells, and 
gene alternations (Speroni et al., 2009;  Yi, Hua, & Lin, 2011). 
 
2.3.2 Naturally Occurring Cancer Animal Models  
 Using spontaneous mammary cancers of other species would be suitable 
as a better model than rodents for human cancer and enhance understanding of 
human carcinogenesis (Cocola et al., 2009). Naturally occurring cancers in dogs 
or cats can be suitable models for study of human glioblastoma on several 
different levels. Cancer in dogs and humans shares strong anatomical and 
physiological similarities, including histological appearance, tumor genetics, 
molecular targets, biological behavior, and response to therapies. Cancer-
associated genetic mutations that promote cancer progression in humans have 
been found in canines. Canine and human cancers also share initiation and 
progression factors, including age, nutrition, gender, reproductive status, and 
environmental exposures. Due to the physiological similarities between dogs and 
humans, several human chemotherapy treatments have been used in veterinary 
medicine as cancer treatment. According to interrogation of the genome 
sequence, approximately 19,000 canine genes match to similar or orthologous 




and molecular signaling pathways have been identified in canine cancers 
(Paoloni & Khanna, 2007). 
 Canine models are able to generate mammospheres and tumourspheres. 
These models have the capacity to be long-term non-adherent cultures and 
generate more complex structures. Canine models also allow for the propagation 
and enrichment of cancer stem-like cells (Pang & Argyle, 2009). The goal of 
studying spontaneous cancer models is to compare for gene identification, 
discover environmental risk factors, understand tumor formation and progression, 
and develop new therapies (Argyle & Khanna, 2006). Accommodation of canine 
GBM models for new drug studies may improve human cancer trials to discover 
new cancer drugs.  
 Naturally occurring canine cancer models are necessary to demonstrate 
the targeting specificity of cancer treatment within a naturally heterogeneous 
tumor environment. Naturally occurring canine models can provide the ability to 
evaluate the potential toxicities and efficacy of this drug and find novel cancer 
treatment (Paoloni & Khanna, 2007). 
 
2.4 Proteomics 
 Proteomics is technology-driven scientific study of proteins, especially 
their changes, proteomes, post-translational modifications, and interactions 
(Fountoulakis, 2001). Proteomics focuses on investigating the structure and 
function of the proteins of the human genome, including the delineation of 




approximately 35,000 genes in the human genome and theoretically 500,000 to 
1,000,000 proteins can be translated (Galvao et al., 2011).  
 Proteomics plays an important role in characterizing cancer addition to 
genomics. Since genomics does not directly translate to proteins, mRNA 
expression data alone is insufficient to predict cellular functions. Addition of 
proteomic data provides access to a global view of molecular changes in different 
stage of diseases. Many disease studies attempt to understand changes in 
protein levels of functions to improve and discover new treatment options. 
Existing drug mechanisms focus on inhibiting the disease-related protein 
activities (Khalil, 2006).   
 Proteomics research focuses on two strategies. The first strategy of 
proteomics is to define protein-protein interactions in order to investigate complex 
networks of intracellular signaling pathways. The second strategy is to monitor 
large-scale global expression of different proteins and quantitatively identify the 
changes of expression patterns (Simpson & Dorow, 2001). Investigations of 
global protein expression are conducted in disease studies to identify biomarkers 
for diagnosis, prognosis, and for identification of therapeutic targets, especially in 
cancer research.  
 
2.4.1 Cancer Proteomics 
 Proteomic approaches are widely used in cancer studies. The goal of 
proteomic analysis in cancer research is to identify new biomarkers for diagnosis 




outcomes (Simpson & Dorow, 2001). Moreover, discovering pathways of cellular 
signaling networks has a potential to eliminate tumor initiation and progression 
(Collins, 2009).  
 Cancer proteomics mainly investigates increased proto-oncogene 
expression, inactivation of tumor suppressor genes, chromosomal instability, 
alterations in DNA repair genes, telomerase reactivation, structural proteins, 
signal-transducers, cell-cycle regulators, and epigenetic alterations that result in 
disregulation of cell proliferation, clonal selection, and tumor formation (Galvao et 
al., 2011; Rodenhiser & Mann, 2006). Quantitative value of protein expression in 
a proteome provides the information on the cell response due to changes in its 
cellular environment. The results of these changes are up- regulated or down-
regulated proteins, which may regulate cellular activities related to tumor initiation, 
progression, and metastasis (Khalil, 2006). Information about oncogenic and 
tumor suppressor proteins and growth factor receptor signaling pathways has 
been provided through proteomics. Proteomics-driven cancer research has the 
potential to define protein-protein interaction networks that lead to tumor 
deregulation and inhibition of cancer progression (Collins, 2009).  
 
2.4.2 Cancer Biomarkers 
 Biomarkers are molecular indicator of a biological status. Biomarkers can 
be detected in the blood, body fluids, or tissues. Discovery of biomarkers in 
cancer is important for several reasons: early detection of cancer, diagnosis, 




decision making for appropriate patient treatment. Tumor biomarkers express 
cancer-specific mutations, or changes in gene expression or promoter 
methylation. These changes can result in alterations in protein expression. 
Cancer-specific protein alterations can be expressed in the protein abundance or 
the modification of post-translational proteins (Tainsky, 2009). The concentration 
of specific biomarkers is highest in the tumor cells and its microenvironment 
(Hondermarck, 2003; Simpson et al., 2008) and combination of several different 
markers affect tumor behavior (Alaiya et al., 2000).  
 There are three main useful markers in cancer: diagnostic, prognostic, and 
predictive markers. These markers provide tumor information about the 
malignant potential and the prognosis. Diagnostic markers are used to help 
histopathological classification. Prognostic markers include hormone receptors, 
proliferation markers, proteases, and angiogenesis markers. These markers are 
used in diagnosis of cancer. Predictive markers are used to decide different 
therapy options (Alaiya et al., 2000).  
 Proteome analysis of glioma has been attempted in different models such 
as human patients’ biopsies and body fluids, human glioma in vitro cell lines, and 
animal models to discover new treatment targets. Proteins that were discovered 
to be significantly up-regulated due to brain tumor grade include GFAP, IGF-
binding protein 2 (IGFBP2), IGFBPS, PBEF1/NAmPRTase (Nicotinamide 
phosphoribosyltransferase, plasminogen activator inhibitor-1 (PAI -1), Cathepsin-
D, YKL-40, MMP9 and low MW Caldesmon (1-CaD). According to the literature, 




retinoblastoma and the p53 pathways (Niclou, Fack, & Rajcevic, 2010). 
Identification and characterization of protein expression changes in the cells have 
potential to discovery the target biomarkers of cancer (Tainsky, 2009). 
 
2.4.3 Limitations 
 Proteomics already plays a huge role in studies of mechanisms of tumor 
formation and identification of proteins for cancer diagnosis and treatment targets 
(Collins, 2009). However, there are still challenges due to several reasons. There 
are two major limitations on the cancer biomarker discovery. First, diverse 
populations of human samples that are collected under various clinical conditions 
are required. Second, discovery phase studies use the predominant retrospective 
samples (Zhang & Chan, 2005).  
The followings are the direct implications of these two biological facts:  
• Complexity of clinical specimen proteome: Human proteomes are complex 
and dynamic. It is important to develop techniques that are less complex 
and with narrower dynamic ranges. 
• Biological variability: Samples from different populations are significant. 
The disease-associated proteomic expression data could be significantly 
different from other expression data.  
• Preanalytical variability: There is insufficient protein information for 
diseases. Proteins samples are often collected under different protocols. 





• Analytical variability: Minimization of analytical procedures variability is 
necessary (Zhang & Chan, 2005). 
There are also several difficulties due to technical challenges: 
• The lack of sensitivity and specificity of detecting low abundant biomarkers 
and complex biological samples (Rai & Chan, 2006).  
• Limited detection technology of genome fraction (Alaiya et al., 2000).  
 
2.5 Metabolomics 
 Metabolomics is the global quantitative study of metabolites using omics 
technologies that utilizes the analytical instrumentation with pattern recognition 
techniques to investigate changes in metabolites. Metabolomic profiling is 
capable of detecting and quantifying metabolites in tissues and biofluids that are 
associated with biological pathways (Beger, 2013). Metabolomics also has been 
employed in discovery of functions of genes and proteins. Findings of 
metabolomics provide insights into biological processes (Patti, Yanes, Siuzdak, 
2012). Metabolites play important roles in cellular functions, including cell 
signaling, energy transfer, and cell-to-cell interaction (Niedbala et al., 2009). 
Metabolite profiles can be important markers of physiological and pathological 
states. Analysis of metabolites has the potential to solve the questions on the 
mechanism of disease occurrence and progression (Zhang & Du, 2012). 
 Metabolomics measures and monitors changes of small molecules that 




Metabolomics in cancer research plays a critical role in understanding glycolysis 
of tumor cells, which is called the “Warburg Effect”, production of the amino acids, 
nucleotides and lipids that are required for tumor proliferation and vascularization 
by recognizing the patterns of metabolites. The clinical goal of metabolomics is to 
discover cancer biomarkers that are used for diagnosis and prognosis. Applying 
various analytical techniques, metabolomics is able to correlate metabolites and 
biological pathways in order to identify more accurate potential biomarkers 
(Beger, 2013). This research study applied mass spectrometry in cancer 
metabolomics. Using mass spectrometry in metabolomics, thousands of 
metabolites can be rapidly measured with only minimal amount of samples (Patti, 
Yanes, & Siuzdak, 2012).  
 Metabolomic analysis using mass spectrometry has four main steps. 
Firstly, tumor samples are collected and extraction is performed on the biological 
sample to harvest metabolites. Secondly, data is acquired by mass spectrometry. 
Thirdly, bioinformatics tools are used to analyze the data (Beger, 2013). Current 
metabolomics software, such as XCMS, does not output metabolite 
identifications. These bioinformatics tools provide p-values and fold changes in 
intensity between samples. After organizing the metabolites data using 
bioinformatics tools, this data is compared with existing metabolites databases: 
Human Metabolome Database and METLIN. A database match shows a putative 
metabolite assignment. This result should be confirmed with retention time and 
MS/MS data of the samples. However, a database match does not show a fair 




Siuzdak, 2012). The last step of metabolomics analysis is data interpretation 
(Beger, 2013). The peaks that are shown in data are metabolite features and 
correspond to a detected ion with a unique mass-to-charge ratio and a retention 
time. Although metabolomic tools have been improved, there are still limitations. 
The masses of compounds that are detected in global analyses do not match the 
masses in metabolite databases. There are still many metabolites that are 
unknown (Patti, Yanes, & Siuzdak, 2012).  
 
2.5.1 Cancer Metabolism 
 Cancer cells require genetic and epigenetic alterations to maintain tumor 
proliferation and metastasis (Wolf, Agnihotri, & Guha, 2010). Alteration of 
glycolytic metabolism is the most common biological process alteration in cancer 
(Agnihotri et al., 2013). Cancer cells synthesize carbohydrates, fatty acids, amino 
acids, and nucleotides for rapid proliferation (Beger, 2013) by aerobic glycolysis 
rather than mitochondrial oxidative phosphorylation (OXPHOS) and tricarboxylic 
acid (TCA) cycle, which is called the Warburg Effect. Figure 2.3 describes 
metabolic differences between normal and cancer cells. Normal cells produce 
pyruvate from glucose and go through the TCA cycle and the OXPHOS process 
with presence of oxygen to generate 36 ATPs per glucose. However, cancer 
cells convert most glucose to lactate despite the presence of oxygen and 
generate two ATPs per glucose. This anabolic process promotes rapid tumor 
proliferation (Marie & Shinjo, 2011). Glycolysis is a biochemical process that 




and two pyruvate (Berger et al., 2004). Tumors generate more than 50% of ATP 
by glycolysis even with the presence of oxygen. This is called aerobic glycolysis. 
As a result of aerobic glycolysis, an increased level of lactate that is produced 
from pyruvate in order to survive in microenvironment (Wolf et al., 2010). High 
level of lactate requires the activation of biological systems that equilibrate the 
intracellular pH level and may promote acidification of the tumor 
microenvironment (Santos & Schulze, 2012). In cancer environment, pyruvate 
dehydrogenase (PDH) activity is inhibited by pyruvate dehydrogenase kinase 1 
(PDK1), a hypoxia-driven enzyme, and lactate dehydrogenase A (LHDA) activity 
is upregulated. Elaborated level of lactate causes acidic tumor environment and 
promotes tumor invasion (Marie & Shinjo, 2011).  
 GBM uses glycolysis and glutaminolysis to provide metabolic 
macromolecules for the cell proliferation. In GBM in vitro, 90% of glucose and 60% 
of glutamine produce lactate or alanine. GBM cells take advantage of this 
method to increase the cell division velocity by carbon incorporation into biomass. 
Glytaminolysis produces energy required for fatty acid synthesis by NADPH 
production (Marie & Shinjo, 2011). Grade three and four brain tumors often show 
alterations in phophoinositide 3-kinase (PI3K), EGF receptors (EGFR), vascular 
epithelial growth factor (VEGF), and PTEN signaling. According to the Cancer 
Genome Atlas Research Network, whole genome sequencing proved that 
abnormal signaling through the RTK/RAS/PI3K, p53, and retinoblastoma (RB) 




2012). Over-expressed metabolites in GBM include 2-hydroxyglutarate and 
isocitrate dyhydrogenase 1 mutation ( Patti, Yanes, & Siuzdak, 2012).  
 





 Lipidomics is the systems-level analysis that identifies and quantifies 
pathways and networks of cellular lipids species. Lipidomics uses novel 
analytical technologies to understand the classes of lipids, changes in lipid 
metabolism and lipid-mediated signaling pathways, and interactions with other 
lipids, proteins, and other molecules (Wang et al., 2009; Tripathy, 2011). Lipids 
include fats, waxes, sterols, fat-soluble vitamins, monoglycerides, diglycerides 




 There are two main techniques that are utilized to analyze lipids species 
and interactions: liquid chromatography and mass spectrometry (MS) (Tripathy, 
2011). This research study focuses on analysis of lipids using mass spectrometry, 
which is most frequently used in lipidomic research. Mass spectrometry in 
lipidomics provides higher quantitation performance and higher sensitivity than 
other exiting techniques. There are three main MS techniques, which are global 
lipidomic analysis, targeted lipidomic analysis, and novel lipid discovery. Global 
lipidomic analysis identifies and quantifies different types of lipids through a high 
throughput basis. This technique is used to analyze various pathways and lipid 
metabolism, trafficking, and homeostasis. Mapping techniques are used to 
investigate the spatial and temporal associations of lipids. Targeted lipidomics 
analysis is utilized to identify few specific lipid classes. Novel lipid discovery 
focuses on the discovery of novel lipid classes and molecular species (Tripathy, 
2011) 
 
2.6.1 Cancer Lipid Metabolism 
 Most lipids exist in cell membranes comprising the lipid bilayer. Due to the 
membrane organizing properties of lipids, lipids play many important roles in a 
cell, tissue and organ physiology. The main biological functions of lipids are as 
energy storage, structural components of cellular membranes, changes in cell 
membrane composition, cell signaling, endocrine actions, membrane trafficking, 




biochemical reactions in the cells (Tripathy, 2011). Lipids are also co-sorted with 
proteins during the formation of transport carriers (Shevchenko & Simons, 2010).  
Brain tissue contains the highest amount of lipids compared to other organs. 
Human brain consists of 5-15% lipids, 70-83% water, and 7.5-8.5% proteins. The 
most abundant lipids are classified as cholesterol, phospholipids, and 
sphingolipids. White matter contains 27% cholesterol and 45% phospholipids, 
and gray matter contains 20% cholesterol and 67% phospholipids. When 
glioblastoma tumors are formed in the brain, lipid content decreases.   
(Campanella, 1992).  
 Lipid metabolism in cancer environment is regulated by oncogenic 
signaling pathways, and plays an important role in cancer initiation and 
progression (Zhang & Du, 2012). Lipid metabolism alteration may impact 
membrane structure, synthesis and degradation of lipids, homeostasis, and 
signaling functions. Lipid studies in cancer provide evidence that altered lipid 
metabolism supports tumor proliferation, differentiation, and motility (Santos & 
Schulze, 2012). Malignant transformation changes biosynthetic and bioenergetic 
tumor environments (Zhang & Du, 2012). Currently, most cancer lipid metabolism 
research studies focus on the increased level of fatty acid synthesis in the tumor 
environment. Figure 2.4 describes function of fatty acids stimulated by oncogenic 
signaling (Santos & Schulze, 2012). Enzymes that are involved in fatty acid 
synthesis, such as ATP citrate lyase (ACL), acetyl-CoA carboxylase (ACC) and 




fatty acid levels are higher in more aggressive cancer cell lines and high-grade 
primary tumors.  
 
Figure 2.4. Functions of fatty acids in cancer cells (Santos & Schulze, 2012). 
 
 Alternation of lipid metabolism affects the phenotype of cancer cells. Large 
amount of lipids are required for forming the cell membrane when cancer cells 
proliferate (Santos & Schulze, 2012). Cancer cells rely on de novo endogenous 
lipid synthesis rather than exogenous dietary lipid synthesis. De novo lipogenesis 
has many important roles in tumor formation, such as membrane formation, lipid 
molecule signaling, protein modifications, and energy supply for rapid tumor 
proliferation. Fatty acids that are endogenously produced are often esterified to 
phospholipids to meet the needs of tumor formation, including structural building 




signal transduction, polarization, intracellular trafficking, and migration of the 
cancer cells. Lipid molecules that mediate signal transduction, such as 
phosphatidic acid (PA), diacyl-glycerol (DAG), and lysophosphatidic acid (LPA), 
can activate signaling proteins or bind to G protein-coupled receptors (GPCRs) in 
order to control tumor proliferation, survival, and migration. Fatty acid can also go 
through β-oxidation to provide energy for cancer cells. In Akt-overexpressing 
glioblastoma, fatty acid oxidation is sufficient to support tumor cells and prevent 
glucose withdrawal-induced death (Zhang & Du, 2012). 
 Cancer cells frequently exist in hypoxic regions. GBM tumors are 
heterogeneous with pseudopalisading perinecrotic cells in modedate hypoxic 
region (pO2 = 2.5-5%) and infiltrating cancer cells in normal brain oxygen 
conditions (pO2 = 10%) (Wolf et al., 2010). When the oxygen level is low, 
hypoxia-inducible factors (HIFs) are activated. With alternations in Von Hippel-
Lindau (VHL) tumor suppressor, HIF1-α and HIF2-α are stabilized even in 
presence of oxygen. Activation of HIFs may also occur by oncogenic pathways 
and deletion of p53. HIFs play many important roles in tumor growth process. 
Activated HIF upregulates vascular endothelial growth factor and encourages 
angiogenesis. It also promotes tumor cells to stabilize in hypoxic environment by 
anaerobic energy production. HIF1 upregulates the expression of FASN. HIF1 
induces the hypoxia-inducible protein 2, a protein playing a role in deposition of 
neutral lipids into lipid droplets, in order to accelerate the accumulation of lipids. It 
also induces the peroxisome proliferator-activated receptor γ to support free fatty 




environments, glutamine plays an important role in lipid synthesis by providing 
carbon without mitochondrial activity (Santos & Schulze, 2012). 
 Lipid profiles are powerful information for drug and biomarker 
development. Lipid metabolism is potentially used as evidence of the 
identification of pathways. Analysis of lipids with other omics studies will provide 
better understanding of diseases that involve disruption of lipid metabolic 
enzymes and pathways (Tripathy, 2011).  
 
2.6.2 Limitations 
 Lipidomic analysis has been difficult due to the specificity and complexity 
of lipid composition and the lack of techniques for the analysis (Tripathy, 2011). 
Regulation and the mechanisms of lipid compositional complexity associated with 
cell homeostasis are still poorly understood (Shevchenko & Simons, 2010). 
Moreover, mass spectrometry has limitations in the structural identification of 
lipids. Due to various classes and molecular species of lipids, it is extremely 
difficult to accommodate all lipid classes using existing current detection methods.  
In contrast to genomics and proteomics, current lipidomics technologies are not 
capable of predicting the number of individual lipid molecules in an organism. 
Therefore, mapping lipidomes is still unattainable using existing technologies 
(Tripathy, 2011). As a result of the lack of lipidome information, genomic and 
proteomic profiles have not been matched with knowledge of lipids.  Despite the 
fact that identification of protein-lipid interactions is increasing, the structural 





 This chapter has provided an overview to the review of relevant literature. 
It provided information of glioblastoma, existing treatment options, advantages 
and disadvantages of the animal models, proteomics, metabolomics, and 
lipidomics in GBM studies. This chapter confirms that cancer model development 










CHAPTER 3.  METHODOLOGY 
 This study was conducted in order to identify significantly expressed lipids 
and correlate patterns of cancer metabolism that can be compared to 
glioblastoma metabolites and proteins. The workflow of lipidomics contained two 
main parts: biological sample preparation and data analysis (Figure 3.1). 
Biological sample preparation contains harvest and collection of GBM xenograft 
tumor (Figure 3.1-1A-B), and lipid extraction from the tumors (Figure 3.1-1C). 
The lipid fraction was taken and run through RHPLC (Figure 3.1-1D) front-
coupled to Bruker 7T Mass Spectrometer in ESI-FTMS mode (Figure 3.1-1E).  
Data analysis contains raw MS data conversion into a compatible format (Figure 
3.1-2A), data processing performed in mzMINE (Figure 3.1-2B), statistical 
analysis (Figure 3.1-2C), LIPID MAPS database search of top 30 most significant 
lipids (Figure 3.1-2D), and hierarchical clustering of the data (Figure 3.1-2E).  
 This chapter outlines the details of human GBM cell line information, 






Figure 3.1. Overview of lipidomic analysis of GBM workflow. 
 
3.1 Cell Lines and Cell Culture 
 Primary human GBM cell line GBM10 and GBM43 were surgically 
removed and provided from the Mayo Clinic, Rochester, Minnesota. Both cell 
lines were known to be resistant to temozolomide and several molecular 
properties were tested prior to this experiment. GBM10 and GBM43 both 
expressed normal EGFR and PTEN. GBM10 also has wild-type p53, tumor 
suppressor gene that is involved in many biological functions, yet GBM43 has 
mutant p53 (Carlson et al., 2011). Two types of in vivo mouse xenograft models 




the Indiana University School of Medicine. GBM10 and GBM43, which are 
resistant to current therapeutic options and actively investigated by the Brain 
Tumor Working Group of IUSM clinicians and science investigators from Purdue 
University, were propagated in the cerebrum of NOD/SCID mice. These cell lines 
were expanded in in vitro environment for approximately two to three weeks 
before being injected into the mouse xenograft models. 3x106 cells were injected 
into right cerebral hemisphere and flank site of mice. Five mouse models were 
utilized per GBM cell type. Figure 3.2 summarizes the biological sample 









3.2 Mouse Orthotopic Models 
 NOD/Scid mice were obtained from the onsite breeding colony in the In 
Vivo Therapeutics Core at the Indiana University School of Medicine. All studies 
were reviewed and approved by the Indiana University Animal Care and Use 
Committee. GBM10 and GBM43 cells were implanted in the right flank in matrigel 
at 3 x 106 cells per mouse. For intracranial implantation, a digitalized stereotaxic 
delivery system was utilized (David Kopf Instruments, Model 5000 microinjection 
unit, Tujunga, CA). REF-1,2 for stereotaxic delivery of tumor cells, mice were 
placed under general anesthesia (ip injection of 16 mg/kg xylazine and 150 
mg/kg ketamine) and positioned in the stereotaxic device. A digitalized drill 
assembly was used to bore a hole 0.3–mm in depth and 0.8-mm diameter in the 
cranium at a position 0.5-mm anterior and 1.2-mm lateral to the bregmal 
anatomical landmark. Tumor cells (2 x 105 in 10 ml of RPMI medium) were 
introduced slowly using a 10 ml Hamilton syringe at a depth of 3.5 mm at a rate 
of 2 µl/min. Once injection was complete, the needle was kept in place for at 
least 5 minutes and then slowly removed and the hole sealed with bone wax. The 
incision was closed with a wound clip. These models have been validated in past 
studies and the median survival is 21 to 24 days post-implantation of tumor cells. 
Figure 3.3 shows in vivo detection of orthotopic primary GBM10 tumors at week 
three and four by bioluminescent imaging. Mice with flank tumors were 







Figure 3.3. In vivo detection of orthotopic primary GBM10 by bioluminescent 
imaging. 
 
Tumors were excised, flash frozen, and stored at -80oC. For mice with 
intracranial tumors, the mice were observed daily starting at 2 weeks and prior to 
reaching the pre-death endpoint were euthanized. Tumor tissue was excised 
from the right cerebrum and flash frozen and stored at -80oC. Twenty-eight tissue 
samples of GBM10, GBM43 from brain and flank site, and control brains from 








Quantity of tissue samples harvested from GBM xenograft models. 
Cell line Tissue type Amount 
 
GBM10 
Brain tumor 5 




Brain tumor 5 




Mouse xenograft tumor sample information. 
Sample  Mouse ID Cell Type Tumor/Tissue Site 
1 1 GBM10 Brain 
2 1 GBM10 Flank 
3 1 Control Brain 
4 2 GBM10 Brain 
5 2 GBM10 Flank 
6 2 Control Brain 
7 3 GBM10 Brain 
8 3 GBM10 Flank 
9 3 Control Brain 
10 4 GBM10 Brain 
11 4 GBM10 Flank 
12 4 Control Brain 
13 5 GBM10 Brain 
14 5 GBM10 Flank 
15 5 Control Brain 





Table 3.2 (continued). 
Mouse xenograft tumor sample information. 
Sample Mouse ID Cell type Tumor/Tissue site 
17 M-1 GBM43 Brain 
18 M-1 GBM43 Flank 
19 M-2 Control Brain 
20 M-2 GBM43 Brain 
21 M-2 GBM43 Flank 
22 M-3 Control Brain 
23 M-3 GBM43 Brain 
24 M-4 Control Brain 
25 M-4 GBM43 Brain 
26 M-4 GBM43 Flank 
27 M-5 Control Brain 
28 M-5 GBM43 Brain 
29 M-5 GBM43 Flank 
 
 
3.3 Protein, Metabolite and Lipid Extraction 
 Sample preparation of the mouse tumors prior to mass spectrometry was 
performed using a novel biomolecule extraction method to harvest the proteins, 
metabolites, and lipids in one simple and fast procedure.  
 10mg to 100mg of in vivo mouse GBM tumor tissues were placed in a low 
retention 2.0ml microcentrifuge tube and placed on ice. These tumor samples 
were mixed with 200µl of 75% MetOH in 0.15M NaCl. Approximately 50µl of 
grinding balls (ZrO; diameter ~0.5 mm) were added to each tube in order to 
homogenize the tumor tissues using a Next Advance Bullet Blender for two 




After the tissue homogenization, 20µl of suspension from each tube was 
transferred into the new 1.5ml microcentrifuge tubes. The homogenized samples 
were mixed with 180µl of 0.15M NaCl and 1ml of chloroform/methanol (2:1) with 
0.01% BHT by vortex for two minutes, then incubated in room temperature for 30 
minutes. After the incubation, the tubes were centrifuged for five minutes at 
7,800xg. 250µl of the lower chloroform phase of the mixtures were transferred 
into the new tubes and labeled as ‘lipid’ fraction. These lipid fractions were stored 
in -80°C until mass spectrometry was performed. Remaining lipid phase of the 
samples were discarded and briefly vortexed. 100ul of suspension of each 
sample was transferred to the new microcentrifuge tubes. These suspensions in 
the new tubes were mixed with 100µl of MetOH, vortexed, and centrifuged for 
five minutes at maximum speed. The supernatant was transferred to the new 
tubes and labeled as ‘Polar Metabolites’ fraction. These polar metabolite 
fractions were also stored in -80°C. The pellets were washed with cold acetone 
by resuspending and centrifuging. After discarding acetone, the pellets were 
resuspended with the buffer. These mixtures were the ‘protein’ fraction.  
For aniline labeling of polar metabolite fraction, the samples were dried under 
nitrogen. Then, dried samples were resuspended in 100µl of 0.15M NaCl.  
 
3.4 Instrument  
 Mass spectrometry with front-end, reverse phase high-performance liquid 
chromatography (RHPLC) for molecule separation was performed on the sample 




FTMS; 7 T Bruker Instrument). The 26 lipid samples were randomly ordered and 
assigned corresponding designations. Thirty microliters of each sample were 
loaded into the appropriate vials and placed in the auto-sampling tray of an 
Agilent 1200 series HPLC running in the reverse phase with an ACE C8 silica 
column. The column utilized a solvent gradient as described in Table 3.3. The 
auto-sampler loaded 2 µl from each vial, running a methanol blank both prior to 
sampling and twice after each sample to ensure full elution of the sample from 
the column. After elution, each sample ran directly to the mass spectrometer. 
Electrospray ionization (ESI) reduces risk of fragmentation of the lipid during 
ionization. Meanwhile, FTMS provides high mass resolving power relative to 
other modes of mass spectrometry, allowing for enhanced detection of unique 
lipids. The mass spectrometer was run in both positive-ion mode and negative-
ion mode to ensure a complete profile of lipids was achieved. 
 
Table 3.3. 
HPLC gradient parameters for lipid separation in reverse phase using Solvent A 
as 0.1 % formic Acid, 10 mM ammonium acetate in water and Solvent B as 0.1% 
Formic Acid, 10 mM ammonium acetate in acetonitrile: asoproponol in a 1:1 ratio. 
 
Time (minutes) % Solvent A % Solvent B 
0 70 30 
1 70 30 
25 0 100 
45 0 100 
47 70 30 





3.5 Data Analysis 
 Profile data from the mass spectrometry was in the form of peak areas for 
each for recognized masses, which were converted to XML format and imported 
in the open source pre-processing software mzMine2. mzMine2 is a data 
processing tool for LC-MS data and designed for metabolomics profiles. This tool 
was utilized for peak detection, shoulder filtering, isotope removal, and gap filling 
(Pluskal et al., 2010) to compare control brain tissue to brain tumor tissue and 
flank tissue for the GBM10 and GBM43 samples independently. A series of 
homoscedastic t-tests comparing GBM10 and GBM43 brain, flank, and control 
tumors in all possible permutations identified the most significantly differentially 
regulated lipids. A selection of these were identified using LIPID MAPS, a web-
based lipid database, which uses a text/ontology – based search to identify sub 
class, class, and common structure of a lipid within a variable m/z tolerance of 
0.1-5 m/z. 
   
3.6 Summary 
 This chapter has provided an overview to methodology of the research 
project, including the sample harvest, biomolecule extraction, maintenance and 










CHAPTER 4.  PRESENTATION OF THE DATA AND FINDINGS 
 The methodology of this project was performed to answer the research 
questions as introduced in Chapter 1. These questions were (1) what are the 
similarities and differences of molecular profiles between brain (orthotopic) and 
flank (subcutaneous) tumors in mouse xenograft model; and (2) are there 
biomarkers in GBM10 and GBM43 that are related to metabolic properties of 
GBM? 
 This chapter presents the mass spectrometry data that was processed 
with various bioinformatic and statistical tools, and the list of identified lipid 
classes. It also provides the comparison data between two different GBM cell 
lines and two different xenograft models. Detail interpretation of these results and 
further observations are described in Chapter 5.  
 
4.1 Mass Spectrometry Data 
 Among all 26 samples, 11218 unique positive-ion mode peaks were 
quantified by mzMine2, representing an m/z ratio range of 244 to 1,800. To filter 
out insignificant peaks, a truncated data set was created by removing any peak 




model grouping. This yielded 4,422 positive-ion mode peaks. A similar process 
for data ran in the negative-ion mode yielded 725 unique peaks.  
 Of the positive-ion mode data, 368 lipids were identified to be significantly 
different in lipid levels between GBM10 brain tumor tissue and the control tissue, 
305 between GBM43 brain tumor tissue and the control tissue, and 1960 lipids 
between all brain tissue (both GBM10 and GBM43) and all flank tumor tissue. Of 
the negative-ion mode data, 149 lipids were significantly expressed between 
GBM10 brain tissue and the control tissue, 233 between GBM43 brain tissue and 
the control tissue, and 211 lipids between all brain tissue and all flank tissue. 
Summary of the number of significant lipids from different tissue types and the 
ratio of significantly decreased and increased lipids compare to control is shown 
in Table 4.1. More than 500 lipid species were significantly detected per different 
tissue type. More than 90% of these lipids were decreasingly expressed in both 
GBM10 and GBM43. This data clearly reported that GBM tumor tissue contains 
dramatically lower levels of lipid composition than normal brain tissue.  
 
Table 4.1. 
Differentially expressed significant lipids in different types of GBM tissues 
compare to control brain tissues. 
 







Over-expressed 26 21 360 
Under-expressed 342 (92.9%) 284 (93.1%) 1566 (81.3%) 
Negative ion 
mode 
Over-expressed 2 0 4 




4.2 Significantly Expressed Lipids in GBM 
 Since there were over 500 identified lipids from different tissue types, the 
30 most significantly identified lipids from each tissue type, which have p-value 
less than 0.05 and fold effect intensity greater than one, were plotted in order to 
visualize the most differentially expressed lipid classes, which are 
glycerophosphocholines, glycosphingolipids, glycerophosphoethanolamines, 
triradylglycerols, and glycerophosphoserines (Figure 4.1). The x-axis of the graph 
represents the structures of significantly identified lipids and the y-axis shows the 
fold effect change intensity of the lipids compare to control.  
 The positive ion profiles of glycosphingolipids showed similar lipid 
distribution between GBM10 and GBM43 brain tumors. Both types of brain 
tumors showed decreased level of glycosphingolipids. No flank tumor lipids were 
observed on the positive ion plot. However, the negative ion profiles did not show 
any lipids of GBM43, yet did show GBM10 and flank tumors (Figure 4.1 A). 
Mostly under-expressed flank tumor lipids were observed from the positive ion 
profiles. On the other hand, identified lipids from the negative ion profiles were 
equally distributed, mostly showing decreased level of lipids, among GBM10 
brain tumors, GBM43 brain tumors, and all flank tumors. Most significantly 
identified lipids of the negative ion profiles among different tissue types were 
identified as glycerophosphocholines (Figure 4.1 B). Among the significant lipid 
classes, glycerohposphoserines were over-expressed throughout all different 
tissue types. GBM43 showed the highest fold effect change among all different 




expressed higher than flank tumor. The negative ion data only showed the lipids 
from GBM43 and the flank tumors (Figure 4.1 C). The triradylglycerol plot 
showed equally distributed lipids from different tissue types. Some lipids of 
GBM10 and flank tumor were increased, yet majority levels of lipids were 
decreased (Figure 4.1 D). Apart from this distinction, casual observance implied 
that the flank tumor lipid profiles showed greater fold change intensity compare to 
the brain tumor profiles.  
 
4.3 Orthotopic and Subcutaneous Xenograft Tumors 
 Significantly identified lipids between brain tumor tissues and flank tumor 
tissues were compared to investigate the similarities and differences. Table 4.2 
represents the number of identified lipids in flank tumor compared to brain tumor 
tissues. There were a total of 1,960 significantly regulated positive ion lipids and 
206 negative ion lipids in brain tumors compared to flank tumors. As the table 
shows, the majority of significant lipids were decreased in flank tumor tissues. 
Differentially expressed lipids between brain and flank tumors supports the 
pattern on Figure 4.1 and 4.2, which expresses m/z range and different fold 
effect change among the brain tumors and the flank tumors. Generally, lipidomic 













Differentially expressed significant lipids between brain tumors and flank tumors. 
 Number of lipids 
 Positive ion mode Negative ion mode 
Over-expressed 267 7 
Under-expressed 1693  199 
 
 
Figure 4.2. m/z and fold effect comparison of each tissue type. 
 
 
4.4 Hierarchical Clustering of GBM Tumors 
 For quality assurance purposes, a series of statistical approaches were 
employed in order to identify any definite peculiarities with the results. In 





















GBM 10 Brain,  GBM 43 Brain, and Flank vs.  
Control Comparison 




demonstrated affinities consistent with the grouping of the samples. For this 
purpose, a set of clustering algorithms, Divisive ANAlysis (DIANA) and 
AGglomerative NESting Hierarchical Clustering (AGNES), were performed. To 
generate the clusters of the samples, m/z values and peak intensities from 
MzMine2 data were compared. As a result, the output from DIANA and AGNES 
showed similar patterns of clusters while these two algorithms have distinctly 
different paths to generate the output (Kaufman & Rousseeuw, 2009) and have a 
history of use with similar data (Gough et al., 2008).  
 As is evident from Figures 4.3 – 4.6, these disparate approaches 
produced closely related results. All the figures generated from DIANA and 
AGNES showed a propensity for the flank subjects to clearly cluster away from 
the other tissue types while the brain and control groups demonstrate a more 
closely clustered set of results. However, even in the brain and control groups, 
each group tended to segregate in the expected cohorts.  
 Based on the evidence rendered from using DIANA and AGNES, it is 
likely that the results achieve the aforementioned affinities, and accordingly the 
































4.5 Summary  
 This chapter has presented the data from mass spectrometry and various 
approaches to discover significance of the data. Employing bioinformatic tools 
and statistical tests identified significantly expressed lipids from different tissue 
types. Hierarchical clustering methods were also utilized to validate the data 
analysis approaches. 
 The next chapter draws upon the data presented in this chapter in order to 











CHAPTER 5.  DISCUSSION, CONCLUSIONS, AND RECOMMENDATIONS 
 This chapter discusses the results generated by lipidomics workflow and 
mentions any observations that may affect the outcome of the experiment. It also 
summarizes the overall findings of this study and present potential future work to 
support the hypotheses that were drawn.  
 
5.1 Discussion 
5.1.1 GBM Cell Lines and Tumor Sizes 
 In vivo xenograft models were utilized to expand GBM tumor formation for 
the biomolecule extraction since cell viability and growth rate of GBM10 and 
GBM43, known to be resistant to temozolomide, were not consistently stable 
after approximately two to three weeks in in vitro environment. GBM cells were 
incubated in mouse xenograft models from 21 to 24 days in order to harvest 
appropriate size of tumors from viable mouse condition. Figure 5.1 represents 
the tumor sizes due to the different tissue types. The box plot of the tumor size 
showed that the size of GBM43 flank tumors was significantly smaller compared 
to other tumor tissues. GBM43 did not appeared on one of the mouse models so 
that only four GBM43 flank tumors were harvested instead of five. Moreover, 




biomolecule extraction, which was designed for the tissue mass between 10mg 
and 100mg. Morphological differences between different GBM cell lines might be 
related to the tumor formation characteristics in xenograft models since GBM10 
tends to form more localized tumors and GBM43 is known to have more invasive 
properties compare to GBM10.  
  Biomolecule extraction procedure also showed histological differences 
between GBM10 and GBM43. Flank tumor tissues were more difficult to 
homogenize compared to brain tumors and control samples. Control brain and 
brain tumor tissues were mostly homogenized on the first attempt. However, 
most of the flank tumors from GBM10 and GBM43 were homogenized up to five 
times in order to break down the tissue. 
 
 



































5.1.2 Biological Sample Preparation for Mass Spectrometry 
 The protocol for protein, metabolite, and lipid extraction was designed for 
the tissue size between 10mg and 100mg. This protocol was designed to 
overcome current limitations of sample preparation of metabolites and lipids.  
The extraction method was developed to extract proteins, metabolites, and lipids 
from one sample preparation. This method can be beneficial for the sample 
preparation in several ways. First, simple and minimal procedures can save 
sample preparation time, minimize degradation of metabolites, and lower sample 
loss during preparation period. Second, the samples from this protocol include a 
wide range of metabolites and proteins, which is beneficial for untargeted omic 
studies. Third, due to the simple and fast sample preparation steps, the sample 
preparation is easily reproducible. Reproducibility is important in omic studies, 
which use a large number of samples (Vuckovic, 2012).  
 
5.1.3 Data Analysis 
 Quantitative analysis of the significantly differentially regulated lipids 
establishes patterns which indicate noteworthy differences between orthotopic 
and xenographic models of glioblastoma in mice. As previously mentioned, 
cursory analysis using t-tests and manual identification indicated that while 
general lipid profiles of flank tumors and brain tumors appeared to be in similar 
m/z range, comparison of lipid classes showed different lipid contents between 
different tissue types. Statistical validation method, hierarchical clustering, 




brain tumor and brain control tissue, as brain tumor and brain control tissue 
cluster together. This evidence may suggest that brain tumors and control tissues 
were more similar to each other than flank tumor tissues. The clustering output 
may also imply that certain ‘background noise’ from surrounding tissue of the 
tumor (i.e. the variance in lipid composition of brain tissue and flank tissue) can 
account for a small portion of this clustering pattern.  
 Beyond the hierarchical clustering of the data, lipid identification 
introduces an element of uncertainty into the analysis. Because the mass 
spectrometer returned hundreds of significantly differentially regulated lipids, 
many of which shared nearly identical m/z ratios, power of manual analysis is 
influenced by both (1) the resolution of the LipidMaps database and (2) the size 
of the database (containing just over 37,500 unique lipids). The potential of 
fragmentation and creation of adducts within the ion generator, though roughly 
accounted for by mzMine2, adds further complication in manual identification of 
lipids. The instrument used, a Bruker 7-Tesla FT-MS, utilizing the solariX 
platform, provides mass accuracy on the magnitude of greater than under one 
part per million, which greatly increases the certainty of database returns on lipid 
identification. Likewise, the soft-ionization of the electrospray limits fragmentation 
and is compatible with front-coupled RHPLC used to separate lipids prior to 




5.2 Biological Implications 
5.2.1 Lipid Studies and Decreased Level of Lipids in GBM 
 Our data showed that more than 90% of significantly identified lipids from 
in vivo brain and flank GBM tumors were under-expressed compared to the 
control brain tissue. On the other hand, the majority of the studies in cancer lipid 
metabolism have a tendency to focus on increased level of fatty acid synthesis 
(Zhang & Du, 2012). Lipidomic analysis has been difficult due to the specificity 
and complexity of lipid composition and the lack of techniques for the analysis 
(Tripathy, 2011). Regulation and the mechanisms of lipid compositional 
complexity associated with cell homeostasis are still poorly understood 
(Shevchenko & Simons, 2010). Moreover, mass spectrometry has limitations of 
the structural identification of lipids. Due to various classes and molecular 
species of lipids, it is extremely difficult to accommodate all lipid classes using 
existing current detection methods (Tripathy, 2011).  Due to these difficulties in 
lipid studies, many research projects investigated the protein level of tumors to 
study lipid metabolism and not actual composition of lipids in cancer cells. 
 However, few number of lipid studies in gliomas examined the correlation 
between membrane lipid composition and malignancy of astrocytomas. A study 
that was published in 1992 measured membrane lipid changes among different 
grades of human gliomas using HPTLC. This study concluded that higher level of 
malignant glioma has significantly lower level of total plasma membrane lipids in 
tumor tissues (Campanella, 1992). More recent study using mass spectrometry 




total lipid abundance were lower than the low-grade astrocytomas (Eberlin et al., 
2012).  
 Aggressive and high-grade primary cancer cells tend to have higher level 
of free fatty acid/ lipid droplets compared to normal or lower grade tumors. 
Monoacylgylcerol lipase (MAGL), a lipolytic enzyme that breaks down 
monoacylglycerols (MAGs) to produce glycerol and a free fatty acid, are also 
highly up regulated in aggressive form of cancer cells. Inhibition of MAGL 
showed that migration, invasion, and survival characteristics of cancer cells were 
inhibited in vitro and in vivo models (Zhang & Du, 2012). However, the 
mechanism of lipid droplets in cancer cell proliferation and survival is not well 
understood (Santos & Schulze, 2012). Our preliminary data of glioblastoma stem 
cell showed that these stem cells did not show the metabolic patterns of the 
Warburg Effect. If the cancer cell does not depend on glucose consumption, an 
alternative bioenergy mechanism should be utilized to maintain tumor cell 
survival (Liu, 2006).  
 
5.2.2 Lipid Function and Fatty Acid Oxidation 
 Lipid functions in highly proliferating cancer cells are critical for building 
membranes for the cells and high level of lipids are required. The Warburg Effect 
explained that cancer cells utilize aerobic glycolysis rather than mitochondrial 
oxidative phosphorylation (OXPHOS) and tricarboxylic acid (TCA) cycle to 
maintain cancer environment (Tennant, Duran, & Gottlieb, 2010). According to 




cells with rapid growth rate did not show significant amount of glucose utilization, 
which contradicts the Warburg Effect. This result supports the hypothesis that 
GBM may have a different cancer metabolism pattern other than the Warburg 
Effect. There are some cancer types that do not utilize high levels of glucose as 
cancer energy source. Prostate cancer does not depend on glucose for survival. 
Instead, prostate cancer shows increased uptake of fatty acids and upregulated 
beta-oxidation enzymes, which implies that prostate cancer cells depend heavily 
on fatty acid oxidation to maintain proliferation of cancer (Liu, 2006). Fatty acid 
oxidation also has a critical role in the proliferation and survival of leukemia 
(Samudio, et al., 2010). Energy stress and high glucose uptake can lead to 
increased fatty acid oxidation activity. In GBM, fatty acid oxidation contributes to 
energy production and resistance to oxidative and nutrient stress (Santos and 
Schulze, 2012).  
 There were few studies that examined the role of fatty acid oxidation in 
GBM to investigate the significance of fatty acid and cancer survival. These 
studies confirmed that stimulation of fatty aid oxidation provides sufficient energy 
for GBM to maintain cell survival and protect the cells from glucose deprivation. 
Moreover, more aggressive cancer cells lines expressed higher level of free fatty 
acid (Buzzai et al., 2005). This evidence of aggressive GBM and fatty acid 





5.2.3 Signaling Pathways and Lipid Metabolism 
 Our lipidomics data showed significantly lower level of lipids in GBM, 
which does not support the cancer metabolism and signaling pathways. Figure 
5.2 shows the signaling pathways that are related to lipid metabolism in cancer 
environment with mutant p53.  
 
Figure 5.2. Signaling pathways and regulation of lipid metabolism in cancer 
 
According to these cancer signaling pathways with p53 mutation, lipid synthesis 
level is upregulated in order to synthesis necessary lipids to maintain tumor 




alternated in many types of cancer and has various roles in metabolic regulations. 
Approximately 50% of cancer has p53 gene mutations (Maddocks & Vousden, 
2011). Because of that reason, many cancer research projects are investigating 
mutation of p53 and alteration of metabolism in cancer. However, GBM shows 
distinct patterns of p53 mutation and tumor malignancy. Tumor suppressor gene, 
p53, mutations have been found in 25-30% of primary GBM and 60-70% in 
secondary GBM tumor. On the other hand, approximately 50% of lower grade 
glioma show p53 mutation, which explains that higher malignant forms of glioma 
have a less alternated p53 gene (Wang et al., 2009).   
 
5.3 Conclusions 
 GBM10 and GBM43 cell lines were able to form appropriate size of brain 
tumor tissues with relatively healthy mice conditions. However, GBM43 tumors 
from subcutaneous sites were either too small or did not appear. Decreased cell 
growth and viability indicates that these cell lines may not be appropriate for 
long-term in vitro culture environment. 
 Overall, brain and flank tumors in mouse xenograft models showed 
decreased levels of lipids compare to control. Mass and charge ratio, m/z, ranges 
of identified lipids were also similar. However, there were profile differences in 
classes of significant lipids among these two xenograft tissues. Flank tumors also 
showed higher fold effect compared to brain tumors. The homogenizing 
procedure during the biomolecule extraction implied that histological 




clustering data analysis supported that control and brain tumor tissues were 
more closed related to each other than flank tumor tissues.  
 Figure 5.2 presents the classical lipid metabolism pathways in cancer 
environment with mutant p53, which does not match with the decreased lipid 
level from our data. Many studies suggested that aggressive tumors contain 
higher level of free fatty acids for energy source purpose. From this study, GBM 
cells had significantly lower level of lipid contents compared to the normal brain 
tissue. These results implied that GBM might use fatty acid oxidation as the main 
energy source in nutrient deprived cancer environments.  
 Our results do not follow the mutant p53 and lipid metabolism pattern, 
which is increased level of lipids. The lower percentage of p53 mutations in 
primary GBM compared to lower grade of gliomas and relationship between wild-
type p53 and lipid metabolism suggest a hypothesis that GBM might manipulate 
biological functions of the wild-type p53 gene to metastasize and survive.  
 
5.4 Future Recommendations 
 As mentioned in the Lipid Analysis section, we can compare the identified 
significant lipids with known pathways of tumor genesis. We anticipate these 
results will be supported by related metabolomic and proteomic data from the 
same set of samples, especially concerning potential down-regulation of lipid 
concentration in pathogenic tissue as a result of hypothesized oxidative lipid 
metabolism in glioblastoma tumor cells. We hypothesize proteomic data will 




of lipids, while metabolic data will confirm decreased frequency of glycolytic 

























































LIST OF REFERENCES 
Aebersold, R., & Mann, M. (2003). Mass spectrometry-based proteomics. 
 Nature, 422(6928), 198-207. 
 
Agnihotri, S., Burrell, K. E., Wolf, A., Jalali, S., Hawkins, C., Rutka, J. T., & 
 Zadeh, G. (2013). Glioblastoma, a brief review of history, molecular 
 genetics, animal models and novel therapeutic strategies. Archivum 
 immunologiae et therapiae experimentalis, 61(1), 25-41. 
 
Alaiya, A. A., Franzen, B., Auer, G., & Linder, S. (2000). Cancer proteomics: from 
 identification of novel markers to creation of artificial learning models fro 
 tumor classification. Electrophoresis, 21, 1210-1217. 
 
Argyle, D. J., & Khanna, C. (2006). The biology of cancer: small animal clinical 
 oncology (pp. 31-53). Philadelphia: WB Saunders Company. 
 
Barcus, C. (2010). Protein-Protein Interactions: Stem Cells and Peptide Modified 
 Silica Gels (Master’s thesis). Purdue University, West Lafayette, IN.  
 
Beger, R. D. (2013). A review of applications of metabolomics in cancer. 
 Metabolites, 3(3), 552-574. 
 
Berger, F., Gay, E., Pelletier, L., Tropel, P., & Wion, D. (2004). Development of 
 gliomas: Potential role of asymmetrical cell division of neural stem cells. 
 The Lancet Oncology, 5, 511-514. 
 
Bonavia, R., Cavenee, W. K., & Furnari, F. B. (2011). Heterogeneity 












Brennan, C. W., Verhaak, R. G., McKenna, A., Campos, B., Noushmehr, H., 
 Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., 
 Beroukhim, R., Bernard, B., Wu, Chang-Jiun, Genovese, G., Shmulevich, 
 I., Barnholtz-Sloan, J., Lihua, Z., Vegesna, R., Shukla, S. A., Ciriello, G., 
 Yung, W. K., Zhang, W., Sougnez, C., Mikkelsen, T., Aldape, K., Bigner, 
 D. D., Van Meir, E. G., Prados, M., Sloan, A., Black, K. L., Eschbacher, J., 
 Finocchiaro, G., Friedman, W., Andrews, D. W., Guha, A., Iacocca, M., 
 O’Neill, B. P., Foltz, G., Myers, J., Weisenberger, D. J., Penny, R., 
 Kucherlapati, R., Perou, C. M., Hayes, D. N., Gibbs, R., Marra, M., Mills, 
 G. B., Lander, E., Spellman, P., Wilson, R., Sander, C., Weinstein, J., 
 Meyerson, M., Gabriel, S., Laird, P. W., Haussler, D., Getz, G. & Chin, L. 
 (2013). The somatic genomic landscape of glioblastoma. Cell, 155(2), 
 462-477. 
 
Buzzai, M., Bauer, D. E., Jones, R. G., DeBerardinis, R. J., Hatzivassiliou, G., 
 Elstrom, R. L., & Thompson, C. B. (2005). The glucose dependence of 
 Akt-transformed cells can be reversed by pharmacologic activation of fatty 
 acid β-oxidation. Oncogene, 24(26), 4165-4173. 
 
Campanella, R. (1992). Membrane lipids modifications in human gliomas of 
 different degree of malignancy. Journal of neurosurgical sciences, 36(1), 
 11. 
 
Carlson, B. L., Pokorny, J. L., Schroeder, M. A., & Sarkaria, J. N. (2011). 
 Establishment, maintenance, and in vitro and in vivo applications of 
 primary human glioblastoma multiforme (GBM) xenograft models for 
 translational biology studies and drug discovery. Current Protocols in 
 Pharmacology, 14-16. 
 
Chiang, A. C., & Massagué, J. (2008). Molecular basis of metastasis. New 
 England Journal of Medicine, 359(26), 2814-2823. 
 
Chinnaiyan, P., Kensicki, E., Bloom, G., Prabhu, A., Sarcar, B., Kahali, S., 
 Eschrich, S., Qu, X., Forsyth, P., & Gillies, R. (2012). The metabolomic 
 signature of malignant glioma reflects accelerated anabolic metabolism. 
 Cancer research, 72(22), 5878-5888. 
 
Choi, B. D., Archer, G. E., Mitchell, D. A., Heimberger, A. B., McLendon, R. E., 
 Bigner, D. D., & Sampson, J. H. (2009). EGFRvIII!Targeted Vaccination 
 Therapy of Malignant Glioma. Brain Pathology, 19(4), 713-723. 
 
Clarke, J., Butowski, N., & Chang, S. (2010). Recent advances in therapy for 





Cocola, C., Anastasi, P., Astigiano, S., Piscitelli, E., Pelucchi, P., VIlardo, L.,  
 Bertoli, G., Beccaglia, M., Veronesi, M. C., Sanzone, S., Barbieri, O., 
 Reinbold, R. A., Luvoni, G. C., & Zucchi, I. (2009). Isolation of Canine 
 Mammary Cells With Stem Cell Properties and Tumour!Initiating Potential. 
 Reproduction in Domestic Animals, 44, 214-217. 
 
Collins, B. C., Lau, T. Y., O'Connor, D. P., & Hondermarck, H. (2009). Cancer 
 proteomics—an evolving battlefield. EMBO reports, 10(11), 1202-1205. 
 
Eberlin, L. S., Norton, I., Dill, A. L., Golby, A. J., Ligon, K. L., Santagata, S., 
 Cooks, R. G., & Agar, N. Y. (2012). Classifying human brain tumors by 
 lipid imaging with mass spectrometry. Cancer research, 72(3), 645-654. 
 
Fountoulakis, M. (2001). Proteomics: current technologies and applications 
 in neurological disorders and toxicology. Amino Acids, 21(4), 363- 
 381. 
 
Galvão, E. R., Martins, L. M., Ibiapina, J. O., Andrade, H. M., & Monte, S. J. 
 (2011). Breast cancer proteomics: a review for clinicians. Journal of 
 cancer research and clinical oncology, 137(6), 915-925. 
 
Goldstein, I., & Rotter, V. (2012). Regulation of lipid metabolism by p53–fighting 
 two villains with one sword. Trends in Endocrinology & Metabolism. 
 
Gough, E., Oh, C., He, J., Riley, C., Buck, C., & Zhang, X. (2008). Proteome 
 discovery pipeline for mass spectrometry-based proteomics. BMC 
 Bioinformatics, 9(Suppl 7), p21. 
 
Grossman, S. A., Ye, X., Chamberlain, M., Mikkelsen, T., Batchelor, T., Desideri, 
 S., Piantadosi, S. D., Fisher, J., & Fine, H. A. (2009). Talampanel with 
 standard radiation and temozolomide in patients with newly diagnosed 
 glioblastoma: a multicenter phase II trial. Journal of Clinical Oncology, 
 27(25), 4155-4161. 
 
Gupta, G. P., & Massagué, J. (2006). Cancer metastasis: building a framework.  
 Cell, 127(4), 679-695. 
 
Hamahan, D., & Folkman, J. (1997). Patterns and emerging mechanisms of the 
 angiogenesis switch during tumorgenesis. Cell, 86(3), 354-364. 
 
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. cell, 100(1), 
 57-70. 
 
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008). Lung cancer. The New  





Hicklin, D. J., & Ellis, L. M. (2005). Role of the vascular endothelial growth factor 
 pathway in tumor growth and angiogenesis. Journal of Clinical Oncology, 
 23(5), 1011-1027. 
 
Hondermarck, H. (2003). Breast Cancer when proteomics challenges biological 
 complexity. Molecular & Cellular Proteomics, 2(5), 281-291. 
 
Jellinger, K. (1978). Glioblastoma multiforme: Morphology and biology. Acta  
 Neurochirurgica, 42, 5-32. 
 
Kaufman, L., & Rousseeuw, P. J. (2009). Finding groups in data: an introduction 
 to cluster analysis (Vol. 344). John Wiley & Sons. 
 
Kerr, J. F., Winterford, C. M., & Harmon, B. V. (1994). Apoptosis. Its   
 significance in cancer and cancer therapy. Cancer, 73(8), 2013- 
 2026. 
 
Khalil, A. A. (2006). Biomarker discovery: a proteomic approach for brain cancer 
 profiling. Cancer science, 98(2), 201-213. 
 
Khasraw, M., & Lassman, A. B. (2010). Advances in the treatment of malignant 
 gliomas. Current oncology reports, 12(1), 26-33. 
 
Kleihues, P., Burger, P. C., & Scheithauer, B. W. (1993). The new WHO 
 classification of brain tumours. Brain Pathology, 3(3), 255-268. 
 
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., 
 Purow, B. W., Christopher, N., Zhang, W., Park, J. K.,  & Fine, H. A. 
 (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and 
 EGF more closely mirror the phenotype and genotype of primary tumors 
 than do serum-cultured cell lines. Cancer cell, 9(5), 391-403. 
 
Lipsitz, D., Higgins, R. J., Kortz, G. D., Dickinson, P. J., Bollen, A. W., Naydan, D. 
 K., & LeCouteur, R. A. (2003). Glioblastoma multiforme: Clinical findings, 
 magnetic resonance imaging, and pathology in five dogs. Veterinary 
 Pathology, 40, 659-669.  
 
Liu, Y. (2006). Fatty acid oxidation is a dominant bioenergetic pathway in 
 prostate cancer. Prostate cancer and prostatic diseases, 9(3), 230- 234. 
 
Luptrawan, A., Liu, G., & Yu, J. S. (2008). Dendritic cell immunotherapy for 





Maddocks, O. D., & Vousden, K. H. (2011). Metabolic regulation by p53. Journal 
 of molecular medicine, 89(3), 237-245. 
 
Marie, S. K. N., & Shinjo, S. M. O. (2011). Metabolism and brain cancer. Clinics, 
 66, 33-43. 
 
Martens, T., Laabs, Y., Günther, H. S., Kemming, D., Zhu, Z., Witte, L., Hagel, 
 C., Westphal, M., & Lamszus, K. (2008). Inhibition of glioblastoma growth 
 in a highly invasive nude mouse model can be achieved by targeting 
 epidermal growth factor receptor but not vascular endothelial growth factor 
 receptor-2. Clinical Cancer Research, 14(17), 5447-5458. 
 
Meredith Jr, J. E., Fazeli, B., & Schwartz, M. A. (1993). The extracellular matrix 
 as a cell survival factor. Molecular Biology of the Cell, 4(9), 953. 
 
Mitchell, D. A., & Sampson, J. H. (2009). Toward effective immunotherapy for the 
 treatment of malignant brain tumors. Neurotherapeutics, 6(3), 527-538. 
 
Miura, F. K., Alves, M. J. F., Rocha, M. C., Silva, R. D., Oba-Shinjo, S. M., & 
 Marie, S. K. N. (2010). Xenograft transplantation of human malignant 
 astrocytoma cells into immunodeficient rats: an experimental model of 
 glioblastoma. Clinics, 65(3), 305-309. 
 
Murray, K. K., Boyd, R. K., Eberlin, M. N., Langley, G. J., Li, L., & Naito, Y. 
 (2013). Definitions of terms relating to mass spectrometry (IUPAC 
 Recommendations 2013). Pure & Applied Chemistry, 85(7). 
 
Niclou, S. P., Fack, F., & Rajcevic, U. (2010). Glioma proteomics: status and 
 perspectives. Journal of proteomics, 73(10), 1823-1838. 
 
Niedbala, R. S., Mauck, C., Harrison, P., & Doncel, G. F. (2009). Biomarker 
 discovery: validation and decision-making in product development. 
 Sexually transmitted diseases, 36(3), S76-S80. 
 
Oertel, J., von Buttlar, E., Schroeder, H. W., & Gaab, M. R. (2005). Prognosis of 
 gliomas in the 1970s and today. Neurosurgical focus, 18(4), e12-e12. 
 
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P. L., 
 Burkhard, C., Schuler, D., Probst-Hensch, N. M., Maiorka, P. C., Baeza, 
 N., Pisani, P., Yonekawa, Y., Yasargil, M. G., Lutolf, U. M., & Kleihues, P. 
 (2004). Genetic Pathways to Glioblastoma A Population-Based Study. 





Pang, L. Y., & Argyle, D. J. (2009). Using naturally occurring tumours in dogs and 
 cats to study telomerase and cancer stem cell biology. Biochimica et 
 Biophysica Acta, 1792, 380-391. 
 
Paoloni, M. C., & Khanna, C. (2007). Comparative oncology today. Veterinary 
 Clinics of North America: Small Animal Practice, 37(6), 1023-1032. 
 
Paoloni, M., & Khanna, C. (2008). Translation of new cancer treatments from pet 
 dogs to humans. Nature Reviews Cancer, 8(2), 147-156. 
 
Patti, G. J., Yanes, O., & Siuzdak, G. (2012). Innovation: Metabolomics: the 
 apogee of the omics trilogy. Nature reviews Molecular cell biology, 13(4), 
 263-269. 
Pelloski, C. E., & Gilbert, M. R. (2007). Current treatment options in adult 
 glioblastoma.  US Oncological Disease, 105-109. 
  
Pichlmeier, U., Bink, A., Schackert, G., & Stummer, W. (2008). Resection and 
 survival in glioblastoma multiforme: an RTOG recursive partitioning 
 analysis of ALA study patients. Neuro-oncology, 10(6), 1025-1034. 
 
Pike, L. S., Smift, A. L., Croteau, N. J., Ferrick, D. A., & Wu, M. (2011). Inhibition 
 of fatty acid oxidation by etomoxir impairs NADPH production and 
 increases reactive oxygen species resulting in ATP depletion and cell 
 death in human glioblastoma cells. Biochimica et Biophysica Acta (BBA)-
 Bioenergetics, 1807(6), 726-734. 
 
Pluskal, T., Castillo, S., Villar-Briones, A., & Orešič, M. (2010). MZmine 2: 
 modular framework for processing, visualizing, and analyzing mass 
 spectrometry-based molecular profile data. BMC bioinformatics, 11(1), 
 395.  
 
Rai, A. J., & Chan, D. W. (2006). Cancer proteomics: serum diagnostics for 
 tumor marker discovery. Annals of the New York Academy of Sciences, 
 1022(1), 286-294. 
 
Rana, M. W., Pinkerton, H., Thornton, H., & Nagy, D. (1977). 
 Heterotransplantation of human glioblastoma multiforme and meningioma 
 to nude mice. Experimental Biology and Medicine, 155(1), 85-88. 
 
Reardon, D. A., & Wen, P. Y. (2006). Therapeutic advances in the treatment of 
 glioblastoma: Rationale and potential role of targeted agents. The 





Richmond, A., & Su, Y. (2008). Mouse xenograft models vs GEM models for 
 human cancer therapeutics. Disease Models & Mechanisms, 1(2-3), 78-
 82. 
 
Rodenhiser, D., & Mann, M. (2006). Epigenetics and human disease: translating 
 basic biology into clinical applications. Canadian Medical Association 
 Journal, 174(3), 341-348. 
 
Samudio, I., Harmancey, R., Fiegl, M., Kantarjian, H., Konopleva, M., Korchin, B., 
 Kaluarachchi, K., Bornmann, W., Duvvuri, S., Taegtmeyer, H., & Andreeff, 
 M. (2010). Pharmacologic inhibition of fatty acid oxidation sensitizes 
 human leukemia cells to apoptosis induction. The Journal of  clinical 
 investigation, 120(1), 142. 
 
Santos, C. R., & Schulze, A. (2012). Lipid metabolism in cancer. FEBS Journal, 
 279(15), 2610-2623. 
 
Sausville, E. A., & Burger, A. M. (2006). Contributions of human tumor xenografts 
 to anticancer drug development. Cancer Research, 66(7), 3351-3354. 
 
Shevchenko, A., & Simons, K. (2010). Lipidomics: coming to grips with lipid 
 diversity. Nature Reviews Molecular Cell Biology, 11(8), 593-598. 
 
Simpson, R. J., Bernhard, O. K., Greening, D. W., & Moritz, R. L. (2008). 
 Proteomics-driven cancer biomarker discovery: looking to the future. 
 Current opinion in chemical biology, 12(1), 72-77. 
 
Simpson, R. J., & Dorow, D. S. (2001). Cancer proteomics: from signaling 
 networks to tumor markers. TRENDS in Biotechnology, 19, 40-48. 
 
Speroni, L., de los Angeles Bustuoabad, V., Gasparri, J., Chiaramoni, N. S., 
 Taira, M. C., Ruggiero, R. A., & del Valle Alonso, S. (2009). Alternative 
 site of implantation affects tumor malignancy and metastatic potential in 
 mice: Its comparison to the flank model. Cancer biology & therapy, 8(4), 
 375-379. 
 
Stupp, R., Goldbrunner, R., Neyns, B., Schlegel, U., Clement, P., Grabenbauer, 
 G. G., Hegl, M. E., Nippgen, J., Picard, M., & Weller, M. (2007). Phase 
 I/IIa trial of cilengitide (EMD121974) and temozolomide with  concomitant 
 radiotherapy, followed by temozolomide and cilengitide maintenance 
 therapy in patients (pts) with newly diagnosed glioblastoma (GBM). 






Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., 
 Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., Hau, P., 
 Brandes, A. A., Gijtenbeek, J., Marosi, C., Vecht, C. J., Mokhtari, K., 
 Wesseling, P., Villa, S., Eisenhauer, E., Gorlia, T., Weller, M., Lacombe, 
 D., Cairncross J. G., & Mirimanoff, R. O. (2009). Effects of radiotherapy 
 with concomitant and adjuvant temozolomide versus radiotherapy alone 
 on survival in glioblastoma in a randomised phase III study: 5-year 
 analysis of the EORTC-NCIC trial. The lancet oncology, 10(5), 459-466. 
 
Stupp, R., Mason, W. P., Van Den Bent, M. J., Weller, M., Fisher, B., Taphoorn,  
 M. J., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, 
 J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., 
 Cairncross, G., Eisenhauer, E., & Mirimanoff, R. O. (2005). Radiotherapy  
 plus concomitant and adjuvant temozolomide for glioblastoma. New 
 England Journal of Medicine, 352(10), 987-996. 
 
Taillandier, L., Antunes, L., & Angioi-Duprez, K. S. (2003). Models for neuro-
 oncological preclinical studies: solid orthotopic and heterotopic grafts of 
 human gliomas into nude mice. Journal of neuroscience methods, 125(1), 
 147-157. 
 
Tainsky, M. A. (2009). Genomic and proteomic biomarkers for cancer: a 
 multitude of opportunities. Biochimica et Biophysica Acta (BBA)-Reviews 
 on Cancer, 1796(2), 176-193. 
 
Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010). Targeting metabolic 
 transformation for cancer therapy. Nature Reviews Cancer, 10(4), 267-
 277. 
 
Tripathy, K. (2011). Lipidomics: A Promising area in. Journal of Computer 
 Science & Systems Biology, 4(5), 93-98.  
 
Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., 
 Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., 
 O’Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., 
 Jakkula, L., Feiler, H. S., Hodgson, G., James, C. D., Sarkaria, J. N., 
 Brennan, C., Kahn, A., Spellman, P. T., Wilson, R. K., Speed, T. P., Gray, 
 J. W., Meyerson, M., Getz, G., Perou, C. M., & Hayes, D. N. (2010). 
 Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of 
 Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, 
 and NF1, Cancer cell, 17(1), 98-110. 
 
Vuckovic, D. (2012). Current trends and challenges in sample preparation for 
 global metabolomics using liquid chromatography–mass spectrometry. 





Wang, C., Yang, J., & Nie, J. (2009). Plasma phospholipid metabolic profiling and 
 biomarkers of rats following radiation exposure based on liquid 
 chromatography–mass spectrometry technique. Biomedical 
 Chromatography, 23(10), 1079-1085. 
 
Wang, Y., Yang, J., Zheng, H., Tomasek, G. J., Zhang, P., McKeever, P. E., Lee, 
 E. & Zhu, Y. (2009). Expression of mutant p53 proteins implicates a 
 lineage relationship between neural stem cells and malignant 
 astrocytic glioma in  a murine model. Cancer cell, 15(6), 514-526. 
 
Wolf, A., Agnihotri, S., & Guha, A. (2010). Targeting metabolic remodeling in 
 glioblastoma multiforme. Oncotarget, 1(7), 567-577. 
 
Yi, D., Hua, T. X., & Lin, H. Y. (2011). EGFR gene overexpression retained in an 
 invasive xenograft model by solid orthotopic transplantation of human 
 glioblastoma multiforme into nude mice. Cancer investigation, 29(3), 229-
 239. 
 
Zhang, Z., & Chan, D. W. (2005). Cancer proteomics: in pursuit of “true” 
 biomarker discovery. Cancer Epidemiology Biomarkers & Prevention, 
 14(10), 2283-2286. 
 
Zhang, F., & Du, G. (2012). Dysregulated lipid metabolism in cancer. World 
 journal of biological chemistry, 3(8), 167. 
 
Zhang, X. D., Qin, Z. H., & Wang, J. (2010). The role of p53 in cell metabolism. 





































Ha, S. J., Showalter, G., Rickus, J., Cai, S., Wang, H., Liu, W. M., Sarkaria, J. N., 
Springer, J., Adamec, J., Pollok, K. E., & Clase, K. L. (2013). Abstract B37: 
Proteomic and metabolomic analyses of glioblastoma using mass spectrometry. 
Molecular Cancer Therapeutics, 12(11 Supplement), B37-B37. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
